Foster Dykema Cabot & Partners, LLC Royalty Pharma PLC Transaction History
Foster Dykema Cabot & Partners, LLC
- $1.19 Trillion
- Q3 2024
A detailed history of Foster Dykema Cabot & Partners, LLC transactions in Royalty Pharma PLC stock. As of the latest transaction made, Foster Dykema Cabot & Partners, LLC holds 121 shares of RPRX stock, worth $3,127. This represents 0.0% of its overall portfolio holdings.
Number of Shares
121Holding current value
$3,127% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding RPRX
# of Institutions
411Shares Held
285MCall Options Held
293KPut Options Held
126K-
Morgan Stanley New York, NY44.1MShares$1.14 Billion0.09% of portfolio
-
Vanguard Group Inc Valley Forge, PA37.6MShares$972 Million0.02% of portfolio
-
Black Rock Inc. New York, NY23MShares$595 Million0.01% of portfolio
-
Baillie Gifford & CO16.1MShares$417 Million0.35% of portfolio
-
Viking Global Investors LP12MShares$309 Million1.26% of portfolio
About Royalty Pharma plc
- Ticker RPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 437,139,008
- Market Cap $11.3B
- Description
- Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic i...